Biosimilars: evolution of approaches to the development, regulation, life cycle control and interchangeability management-Reference-Cited by-同舟云学术

Biosimilars: evolution of approaches to the development, regulation, life cycle control and interchangeability management

Published:2021-12-01 Issue:3 Volume: Page:56-68
ISSN:2658-3534
Container-title:Remedium
language:
Short-container-title:jour

Author:

Niyazov Ravil R.¹,Dranitsyna Margarita A.¹,Vasiliev Andrey N.¹,Gavrishina Elena V.¹

Affiliation:

1. Center of Scientific Advice

Abstract

The legal framework for biosimilar medicinal product was first established in 2004 in the European Union and later in the USA. Since then, based on the scientific and regulatory experience with biosimilarity assessment, regulatory approaches have evolved considerably. A clear understanding of the capabilities of each development stage in assessing comparability in terms of power to identify differences and assess their relevance to the final clinical outcome gradually accumulated. In addition to the commitment to the biosimilarity approach, it is important to comply with the general requirements applicable to any drugs produced at an industrial scale. Experience showed that the demonstration of biosimilarity based on a range of analytical and functional tests and mainly clinical pharmacological studies is universal and allows extrapolating therapeutic indications. The establishment of biosimilar interchangeability, since the active substance by definition is a version of the active substance of the corresponding reference biological product, can introduce additional difficulties. A single approach to the establishment of biosimilar interchangeability has not yet been developed.

Publisher

Remedium, Ltd.

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference66 articles.

1. European Parliament, Council. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. EUR-Lex. [Electronic resource]. 31 March 2004. [Tsit.: 9 June 2020]. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32004L0027.

2. European Medicenes Agency. Guideline on similar biological medicinal products — First version. Official Website of European Medicenes Agency. [Electronic resource]. 30 October 2005. [Tsit.: 9 June 2020]. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guidelinesimilar-biological-medicinal-products-first-version_en.pdf.

3. U.S. Congress. U.S. Code, Title 42, Section 262. Regulation of biological products. Legal Information Institute, Cornell Law School. [Electronic resource]. 23 March 2010. [Tsit.: 6 June 2020]. Available at: https://www.law.cornell.edu/uscode/text/42/262.

4. U.S. Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry. Official Website of the U.S. Food and Drug Administration. [Electronic resource]. 28 April 2015. [Tsit.: 29 May 2020]. Available at: https://www.fda.gov/media/82647/download.

5. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product, Guidance for Industry. Official Website of the U.S. Food and Drug Administration. [Electronic resource] 2015. [Tsit.: 5 June 2020]. Available at: https://www.fda.gov/media/135612/download.